Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data
- 1 January 2021
- journal article
- review article
- Published by Elsevier BV in Pharmacological Research
- Vol. 163, 105332
- https://doi.org/10.1016/j.phrs.2020.105332
Abstract
No abstract availableThis publication has 49 references indexed in Scilit:
- Modelling dynamics in protein crystal structures by ensemble refinementeLife, 2012
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsThe New England Journal of Medicine, 2011
- Aldosterone Synthase Inhibition With LCI699Hypertension, 2010
- Rapid Reversal of Left Ventricular Hypertrophy and Intracardiac Volume Overload in Patients With Resistant Hypertension and HyperaldosteronismHypertension, 2010
- Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitorsAnalytical Biochemistry, 2009
- Structural basis for androgen specificity and oestrogen synthesis in human aromataseNature, 2009
- Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerizationCardiovascular Research, 2008
- Inference of Macromolecular Assemblies from Crystalline StateJournal of Molecular Biology, 2007
- Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristicsJournal of Computer-Aided Molecular Design, 2007
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureThe New England Journal of Medicine, 1999